Seeing Is Believing
Currently out of the existing stock ratings of Gregory Renza, 149 are a BUY (81.87%), 33 are a HOLD (18.13%).
Analyst Gregory Renza, currently employed at RBC, carries an average stock price target met ratio of 36.34% that have a potential upside of 28.95% achieved within 94 days.
Gregory Renza’s has documented 362 price targets and ratings displayed on 31 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on NRIX, Nurix Therapeutics at 12-Jul-2024.
Analyst best performing recommendations are on RXDX (PROMETHEUS BIOSCIENCES).
The best stock recommendation documented was for RXDX (PROMETHEUS BIOSCIENCES) at 12/7/2022. The price target of $111 was fulfilled within 1 day with a profit of $15.2 (15.87%) receiving and performance score of 158.66.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Buy
28
$10.25 (57.75%)
30
14 days ago
16/20 (80%)
$10.23 (57.57%)
184
Buy
29
$11.25 (63.38%)
35
1 months 1 days ago
10/17 (58.82%)
$13.4 (85.90%)
235
Hold
22
$4.25 (23.94%)
30
2 months 16 days ago
6/7 (85.71%)
$6.75 (44.26%)
281
Buy
28
$10.25 (57.75%)
40
2 months 17 days ago
0/2 (0%)
$12.79 (84.09%)
Hold
21
$3.25 (18.31%)
27
2 months 17 days ago
13/17 (76.47%)
$5.79 (38.07%)
88
Which stock is Gregory Renza is most bullish on?
Which stock is Gregory Renza is most reserved on?
What Year was the first public recommendation made by Gregory Renza?